We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Gregory Cote

Gregory A. Cote MD, MS

Professor of Medicine, Medical University of South Carolina, Charleston, South Carolina
Dr. Cote’s clinical research program focuses on outcomes research in pancreatobiliary diseases including acute and chronic pancreatitis, pancreatic ductal adenocarcinoma and its precursors, bile duct strictures, and gallstone-related diseases. A principal focus of these studies includes outcomes research in pancreatobiliary endoscopy, which includes endoscopic ultrasound (http://ddc.musc.edu/public/procedures/eus.html) and endoscopic retrograde cholangiopancreatography (http://ddc.musc.edu/public/procedures/ercp.html). Dr. Cote is the Principal Investigator for the SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial, a sham controlled, international, multi center, randomized clinical trial evaluating the role of endoscopic minor papillotomy in the treatment of patients with recurrent acute pancreatitis and pancreas divisum. He is also the Principal Investigator for the Results of Ercp in SPhincter of Oddi Dysfunction (RESPOnD) study, a multicenter, longitudinal cohort study evaluating the role of ERCP and sphincterootmy in the treatment of patients with Sphincter of Oddi Dysfunction and idiopathic recurrent acute pancreatitis.

Disclosures

Dr. Cote reports the following:
  • Educational speaker – Abbvie and Boston Scientific Corp.
  • Consultant – Olympus Corporation and Cook Medical